Effectiveness of Probiotic for Primary Prevention of Clostridium difficile Infection: A Single-Center Before-and-After Quality Improvement Intervention at a Tertiary-Care Medical Center

Infection Control and Hospital Epidemiology

Volumn 39, Issue 7, 2018, Pages 765-770

  Trick, William E ^a   Sokalski, Stephen J ^b   Johnson, Stuart ^c   Bunnell, Kristen L ^d   Levato, Joseph ^b   Ray, Michael J ^a   Weinstein, Robert A ^a  

^a Collaborative Research Unit ^*  (United States)

^b ADVOCATE CHRIST MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; PROBIOTIC AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM DETECTION; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; ENTERIC FEEDING; EVALUATION STUDY; FECES ANALYSIS; HOME CARE; HOSPITAL BASED CASE CONTROL STUDY; HOSPITAL PATIENT; HOSPITAL POLICY; HUMAN; INCIDENCE; INFECTION PREVENTION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NONHUMAN; NURSING HOME; OBSERVATIONAL STUDY; PEPTIC ULCER; POLYMERASE CHAIN REACTION; PRIMARY PREVENTION; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; TOTAL QUALITY MANAGEMENT; CLOSTRIDIUM INFECTION; COMPARATIVE STUDY; CROSS INFECTION; ILLINOIS; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; TEACHING HOSPITAL; TERTIARY CARE CENTER;

CASE-CONTROL STUDIES; CHICAGO; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; HOSPITALS, TEACHING; HUMANS; PRIMARY PREVENTION; PROBIOTICS; QUALITY IMPROVEMENT; TERTIARY CARE CENTERS;

EID: 85046035670     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1017/ice.2018.76     Document Type: Article

References (28)

1. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. New Engl J Med 2006;355:2725-2732.
2. Gerding DN, Muto CA, Owens RC. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008;46:S43-S49.
3. Trick WE, Temple RS, Chen D, Wright MO, Solomon SL, Peterson LR. Patient colonization and environmental contamination by vancomycin-resistant enterococci in a rehabilitation facility. Arch Phys Med Rehab 2002;83:899-902.
4. Sethi AK, Al-Nassir WN, Nerandzic MM, Donskey CJ. Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2009;30:13-17.
5. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-415.
6. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(Suppl 1):S81-S92.
7. Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA 2003;290:1899-1905.
8. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990;336:97-100.
9. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Libr 2013.
10. Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med 2016;9:27-37.
11. Johnson S, Maziade PJ, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012;16:786-792.
12. Beausoleil M, Fortier N, Guenette S, et al. Effect of a fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Canad J Gastroenterol 2007;21:732-736.
13. Sampalis J, Psaradellis E, Rampakakis E. Efficacy of BioK+ CL1285 in the reduction of antibiotic-associated diarrhea-a placebocontrolled double-blind randomized, multi-center study. Arch Med Sci 2010;6:56-64.
14. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Doseresponse efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636-1641.
15. Maziade P-J, Andriessen J, Pereira P, Currie B, Goldstein E. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 2013;29:1341-1347.
16. Goldstein EJ, Citron DM, Claros MC, Tyrrell KL. Bacterial counts from five over-the-counter probiotics: are you getting what you paid for? Anaerobe 2014;25:1-4.
17. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007;28:140-145.
18. Longtin Y, Paquet-Bolduc B, Gilca R, et al. Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of c difficile infections: a quasi-experimental controlled study. JAMA Intern Med 2016;176:796-804.
19. Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003; 24:251-256.
20. Averill RF, McCullough EC, Goldfield N, Hughes JS, Bonazelli J, Bentley L. 3M APR DRG classification system: methodology overview. Agency for Healthcare Research and Quality website. https://www. hcup-us. ahrq. gov/db/nation/nis/grp031-aprdrg-meth- ovrview. pdf. Published 2013. Accessed July 6, 2017.
21. Hernan MA, Robins JM. Per-protocol analyses of pragmatic trials. New Engl J Med 2017;377:1391-1398.
22. Weber DJ, Rutala WA, Miller MB, Huslage K, Sickbert-Bennett E. Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, Clostridium difficile, and Acinetobacter species. Am J Infect Control 2010;38:S25-S33.
23. Samore MH, Venkataraman L, DeGirolami PC, Arbeit RD, Karchmer AW. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996;100:32-40.
24. Halpin AL, McDonald LC. The dawning of microbiome remediation for addressing antibiotic resistance. Clin Infect Dis 2016;62:1487-1488.
25. Freedberg DE, Salmasian H, Cohen B, Abrams JA, Larson EL. Receipt of antibiotics in hospitalized patients and risk for Clostridium difficile infection in subsequent patients who occupy the same bed. JAMA Intern Med 2016;176:1801-1808.
26. Aroutcheva A, Auclair J, Frappier M, et al. Importance of molecular methods to determine whether a probiotic is the source of lactobacillus bacteremia. Probiot Antimicrob Prot 2016;8: 31-40.
27. McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur Gastroen J 2015;4:546-561.
28. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012;157: 878-888.